• Je něco špatně v tomto záznamu ?

Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer

S. Boukalova, J. Stursa, L. Werner, Z. Ezrova, J. Cerny, A. Bezawork-Geleta, A. Pecinova, L. Dong, Z. Drahota, J. Neuzil,

. 2016 ; 15 (12) : 2875-2886. [pub] 20161007

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023607

Grantová podpora
NV16-31604A MZ0 CEP - Centrální evidence projektů

Pancreatic cancer is one of the hardest-to-treat types of neoplastic diseases. Metformin, a widely prescribed drug against type 2 diabetes mellitus, is being trialed as an agent against pancreatic cancer, although its efficacy is low. With the idea of delivering metformin to its molecular target, the mitochondrial complex I (CI), we tagged the agent with the mitochondrial vector, triphenylphosphonium group. Mitochondrially targeted metformin (MitoMet) was found to kill a panel of pancreatic cancer cells three to four orders of magnitude more efficiently than found for the parental compound. Respiration assessment documented CI as the molecular target for MitoMet, which was corroborated by molecular modeling. MitoMet also efficiently suppressed pancreatic tumors in three mouse models. We propose that the novel mitochondrially targeted agent is clinically highly intriguing, and it has a potential to greatly improve the bleak prospects of patients with pancreatic cancer. Mol Cancer Ther; 15(12); 2875-86. ©2016 AACR.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023607
003      
CZ-PrNML
005      
20240314092852.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1535-7163.MCT-15-1021 $2 doi
035    __
$a (PubMed)27765848
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Boukalova, Stepana $u Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic. j.neuzil@griffith.edu.au stepana.boukalova@ibt.cas.cz.
245    10
$a Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer / $c S. Boukalova, J. Stursa, L. Werner, Z. Ezrova, J. Cerny, A. Bezawork-Geleta, A. Pecinova, L. Dong, Z. Drahota, J. Neuzil,
520    9_
$a Pancreatic cancer is one of the hardest-to-treat types of neoplastic diseases. Metformin, a widely prescribed drug against type 2 diabetes mellitus, is being trialed as an agent against pancreatic cancer, although its efficacy is low. With the idea of delivering metformin to its molecular target, the mitochondrial complex I (CI), we tagged the agent with the mitochondrial vector, triphenylphosphonium group. Mitochondrially targeted metformin (MitoMet) was found to kill a panel of pancreatic cancer cells three to four orders of magnitude more efficiently than found for the parental compound. Respiration assessment documented CI as the molecular target for MitoMet, which was corroborated by molecular modeling. MitoMet also efficiently suppressed pancreatic tumors in three mouse models. We propose that the novel mitochondrially targeted agent is clinically highly intriguing, and it has a potential to greatly improve the bleak prospects of patients with pancreatic cancer. Mol Cancer Ther; 15(12); 2875-86. ©2016 AACR.
650    _2
$a zvířata $7 D000818
650    _2
$a antimetabolity antitumorózní $x chemie $x farmakologie $7 D000964
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a respirační komplex I $x antagonisté a inhibitory $x chemie $x metabolismus $7 D042967
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a koncentrace vodíkových iontů $7 D006863
650    _2
$a membránový potenciál mitochondrií $7 D053078
650    _2
$a metformin $x chemie $x farmakologie $7 D008687
650    _2
$a myši $7 D051379
650    _2
$a mitochondrie $x účinky léků $x metabolismus $7 D008928
650    _2
$a molekulární modely $7 D008958
650    _2
$a molekulární konformace $7 D008968
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a spotřeba kyslíku $7 D010101
650    _2
$a nádory slinivky břišní $x farmakoterapie $x metabolismus $x patologie $7 D010190
650    _2
$a vazba proteinů $7 D011485
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a reaktivní formy kyslíku $x metabolismus $7 D017382
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a tumor burden $x účinky léků $7 D047368
650    _2
$a xenogenní modely - testy antitumorózní aktivity $7 D023041
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stursa, Jan $u Institute of Chemical Technology in Prague, Czech Republic.
700    1_
$a Werner, Lukas $u Institute of Chemical Technology in Prague, Czech Republic. Biomedical Research Centre, University Hospital Hradec Kralove, Czech Republic.
700    1_
$a Ezrova, Zuzana $u Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic.
700    1_
$a Cerny, Jiri $u Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic.
700    1_
$a Bezawork-Geleta, Ayenachew $u School of Medical Science, Griffith University, Southport, Qld, Australia.
700    1_
$a Pecinova, Alena $u Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Dong, Lanfeng $u School of Medical Science, Griffith University, Southport, Qld, Australia.
700    1_
$a Drahota, Zdeněk, $d 1932- $u Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic. $7 jn20000400531
700    1_
$a Neuzil, Jiri $u Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic. j.neuzil@griffith.edu.au stepana.boukalova@ibt.cas.cz. School of Medical Science, Griffith University, Southport, Qld, Australia.
773    0_
$w MED00006616 $t Molecular cancer therapeutics $x 1538-8514 $g Roč. 15, č. 12 (2016), s. 2875-2886
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27765848 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20240314092846 $b ABA008
999    __
$a ok $b bmc $g 1239288 $s 984520
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 15 $c 12 $d 2875-2886 $e 20161007 $i 1538-8514 $m Molecular cancer therapeutics $n Mol Cancer Ther $x MED00006616
GRA    __
$a NV16-31604A $p MZ0
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace